Comerica Bank reduced its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) by 22.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 98,127 shares of the biotechnology company’s stock after selling 27,845 shares during the quarter. Comerica Bank owned about 0.06% of Ironwood Pharmaceuticals worth $1,031,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also bought and sold shares of the company. Deutsche Bank AG increased its stake in shares of Ironwood Pharmaceuticals by 412.0% during the second quarter. Deutsche Bank AG now owns 3,442,750 shares of the biotechnology company’s stock valued at $39,695,000 after buying an additional 2,770,309 shares during the period. State Street Corp increased its position in Ironwood Pharmaceuticals by 31.2% during the 2nd quarter. State Street Corp now owns 10,886,805 shares of the biotechnology company’s stock valued at $125,525,000 after purchasing an additional 2,589,738 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Ironwood Pharmaceuticals by 73.4% in the 2nd quarter. Renaissance Technologies LLC now owns 5,415,353 shares of the biotechnology company’s stock valued at $62,439,000 after purchasing an additional 2,292,300 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Ironwood Pharmaceuticals by 380.4% in the 2nd quarter. Principal Financial Group Inc. now owns 1,227,803 shares of the biotechnology company’s stock valued at $14,157,000 after purchasing an additional 972,231 shares in the last quarter. Finally, Pacer Advisors Inc. lifted its position in shares of Ironwood Pharmaceuticals by 36.3% in the 3rd quarter. Pacer Advisors Inc. now owns 1,271,453 shares of the biotechnology company’s stock worth $13,172,000 after purchasing an additional 338,287 shares during the period.
In related news, CEO Thomas A. Mccourt sold 110,962 shares of the business’s stock in a transaction on Thursday, January 5th. The stock was sold at an average price of $12.07, for a total transaction of $1,339,311.34. Following the transaction, the chief executive officer now directly owns 712,440 shares in the company, valued at approximately $8,599,150.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 13.10% of the company’s stock.
Ironwood Pharmaceuticals Price Performance
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Rating) last posted its quarterly earnings data on Thursday, November 3rd. The biotechnology company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. The firm had revenue of $108.64 million during the quarter, compared to analyst estimates of $111.51 million. Ironwood Pharmaceuticals had a net margin of 39.85% and a return on equity of 30.24%. Research analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 1 earnings per share for the current fiscal year.
Analyst Ratings Changes
Separately, StockNews.com downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 17th.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.
- Get a free copy of the StockNews.com research report on Ironwood Pharmaceuticals (IRWD)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.